Home > Focus Areas > Aortic Stenosis Connect > Post
  • Saved

4yr
Outcomes of transcatheter aortic valve replacement for pure native aortic regurgitation with the use of newer- vs. early-generation devices - PubMed

Outcomes of transcatheter aortic valve replacement for pure native aortic regurgitation with the use of newer- vs. early-generation devices - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/35242869/

1 Heart Center, Cheng Hsin General Hospital, Taipei. 2 Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei. 3 Institute of Microbiology and Immunology, School of Medicine, National Yang Ming Chiao Tung University, Taipei. 4 Faculty of Medicine, National Defense Medical Center, Taipei.



Conclusions: Evidently, the treatment of PNAR with TAVR using the newer-generation THVs yielded better procedural outcomes and is a valuable therapeutic option in selective patients.

  • 4yr
    Key Points
    • Source: Cureus
    • Conclusion/Relevance: “Evidently, the treatment of PNAR [pure native aortic valve regurgitation] with TAVR using the newer-generation THVs [transcatheter heart valves] yielded better procedural outcomes and is a valuable therapeutic option in selective patients.”
    • In the current study, researchers compared the use of early- vs. newer-generation TAVRs in 25 patients at intermediate to high risk for surgical aortic valve replacement. The primary outcome was all-cause mortality, myocardial infarction, stroke, and rehospitalization due to heart failure.
    • Success rates of the newer THVs was higher in newer- vs. early-generation CoreValve (100% vs. 33%, respectively, P< ). This difference was mostly due to the decreased need for implanting a second THV. Second-generation THV recipients also needed less fluoroscopic time with less contrast required as well.
    • Lengths of ICU stay were comparable in both groups, with no differences in all-cause mortality, non-fatal MI, non-fatal stroke, or hospital readmission due to heart failure.
    • “Despite the fact that newer-generation devices have achieved lower rates of valve malposition, second valve insertion, and significant residual PVL [paravalvular leakage], their clinical results are overall worse than those of the TAVR for aortic stenosis. Actually, the need for permanent pacemaker implantation (PPI) has not been improved with newer-generation self-expanding device,” the authors wrote.
    • The authors wrote, “Although it has been consistently shown that newer-generation THVs in TAVR for PNAR are associated with more device success, one key determinant for the success of newer-generation devices is the development of dedicated TAVR devices for PNAR.”